Summit Therapeutics plc : Interim 24-Week Data from PhaseOut DMD

Summit Therapeutics plc have announced positive 24-week interim data from PhaseOut DMD, their Phase 2 clinical trial of the utrophin modulator ezutromid. The data showed a significant reduction in muscle damage and an increase in utrophin in muscle biopsies.Read more

Updated Care Consideration Guidelines for Duchenne Published:

Yesterday, the new Care Considerations for Duchenne were published. We strongly encourage all parents, caregivers and patients to read these updates to the standards of care to ensure that everyone living with Duchenne has access to the best possible careRead more

Duchenne UK collaborate with Whizz-Kidz to win £1 million from People's Postcode Lottery Dream Fund

The Wheels of Change project is announced as the winner of People’s Postcode Lottery Dream Fund with £1 million going towards helping transform the futures of young wheelchair users across the UK.Read more

Project HERCULES in the media

We’re pleased to share the latest coverage of Hercules. The launch of the project, with our seven industry partners, has received coverage in 10 publications. HERCULES is collaboration between Duchenne UK, and pharmaceutical companies to increase the chances of patients with DMD of accessing innovative treatments.Read more

Marshall Wace names Duchenne UK as their charity of the year

Duchenne UK is delighted to have been chosen by Marshall Wace as their charity of the year and to be awarded a donation of $100,000. The donation from Marshall Wace will fund 10 boys with Duchenne on our Tamoxifen Trial.Read more

Pharmaceutical industry leaders join forces to pioneer novel approach to Health Technology Assessment

Pfizer, PTC Therapeutics International, Roche, Sarepta Therapeutics, Solid Biosciences, Summit, and Wave Life Sciences are sponsoring Project HERCULESRead more

DMD Hub First Year Round-up

The DMD-Hub was created by Duchenne UK and leading neuromuscular clinicians. The DMD-Hub is addressing the lack of capacity in the UK for clinical trials in DMD. During the first year of operation the DMD Hub has successfully achieved, even surpassed, the immediate priorities identified through the Newcastle Plan.Read more

Congratulations to Joining Jack for winning the Dubai 7's

We would like to congratulate the Joining Jack team for their recent victory! Joining Jack took a team to the Dubai 7's international rugby competition, and they came back champions! Alex Johnson, founder of Joining Jack and Jacks Mum, tells us more about Joining Jack's victory at the Dubai 7s.Read more

Duchenne UK are offering FREE copies of Janet Hoskin's DMD guide

Today, December 14th, marks the publication of Janet Hoskin's book: 'A Guide to Duchenne Muscular Dystrophy: Information and Advice for Teachers and Parents'. We are offering free copies to families affected by DMD, please contact us to request a copy.Read more

Duchenne UK round up of 2017

It has been a busy year at Duchenne UK. Our mission is to fund and accelerate treatments and find a cure for Duchenne muscular dystrophy. We look at where we can add value to the drug development pathway, and how we can help to accelerate research that will benefit the whole community.Read more

Santhera Pharmaceuticals, Summit Therapeutics, Catabasis Pharmaceuticals and Duchenne UK to host DMD Awareness Day

Our co-founder, Emily Crossley, is chairing a Duchenne Muscular Dystrophy Awareness Day. Speaking at the conference, will be some of the leading professionals in this field.Read more

Haelan 951 research has promising results

Duchenne UK commissioned Professor Steve Winder at Sheffield University to investigate a nutraceutical soy product, called Haelan 951. Haelan 951 has been popular with some DMD families as a perceived way of slowing down disease progression. Steve Winders poster summarises the results.Read more